Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | LPL | P06858 | 2/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.39 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17367527 | 0.89 | CA2 (0.44) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL40868 | 0.82 | CA2 (0.52) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL29817989 | 0.82 | CA2 (0.52) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL29957514 | 0.78 | TP53 (0.52) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL2010727 | 0.78 | TP53 (0.52) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL29591086 | 0.77 | TDP1 (0.50) | CA2LPLLIPGORAI1ORAI2 | |
| SCHEMBL42414 | 0.77 | TDP1 (0.50) | CA2LPLLIPGORAI1ORAI2 | |
| SCHEMBL3194289 | 0.76 | ALDH1A1 (0.50) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL5839148 | 0.76 | CA2 (0.46) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL177567 | 0.76 | CA2 (0.46) | CA2LPLLIPGCA1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144838-A1 | THERANOSTIC SYSTEM FOR DIRECTED DIFFUSION OF THERAPEUTIC AND IMAGING AGENTS TO CANCER CELLS | UNIVERSITAT POLITÈCNICA DE VALÈNCIA (ES) | 2023-05-11 | — | — | US | disclosed |
| US-20150380655-A1 | ANTHRACENE DERIVATIVE, METHOD FOR PREPARING THE SAME, USE THEREOF AND ORGANIC LIGHT EMITTING DEVICE | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2015-12-31 | — | — | US | disclosed |
| US-20150380655-A1 | ANTHRACENE DERIVATIVE, METHOD FOR PREPARING THE SAME, USE THEREOF AND ORGANIC LIGHT EMITTING DEVICE | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2015-12-31 | — | — | US | disclosed |
| EP-1378532-B1 | POLYMER CONTAINING 9-OXO-9-PHOSPHAFLUORENE-2,7-DIYL SKELETON IN BACKBONE AND PROCESS FOR PRODUCING THE SAME | JAPAN SCIENCE & TECH AGENCY (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-7033680-B2 | Electroluminescent element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-6949621-B2 | Polymer containing 9-oxo-9-phosphafluorene-2,7-diyl skeleton in backbone and process for producing the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20050106413-A1 | Electroluminescent element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| US-20040019180-A1 | Polymer containing 9-oxo-9-phosphafluorene-2,7-diyl skeleton in backbone and process for producing the same | EFFECTO, INC. | 2004-01-29 | — | — | US | disclosed |
| EP-1378532-A1 | POLYMER CONTAINING 9-OXO-9-PHOSPHAFLUORENE-2,7-DIYL SKELETON IN BACKBONE AND PROCESS FOR PRODUCING THE SAME | Japan Science and Technology Corporation (JP) | 2004-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144838-A1 | THERANOSTIC SYSTEM FOR DIRECTED DIFFUSION OF THERAPEUTIC AND IMAGING AGENTS TO CANCER CELLS | FOLR1, EGFR, FOLR2 | CA2 1619/4885LPL 3725/4885LIPG 1749/4885 |
| US-20150380655-A1 | ANTHRACENE DERIVATIVE, METHOD FOR PREPARING THE SAME, USE THEREOF AND ORGANIC LIGHT EMITTING DEVICE | ALAD, PPOX, CYBA | CA2 3244/4885LPL 1597/4885LIPG 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.